Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS is active in the Biotechnology & Pharmaceuticals technology area. The current state of their patent prosecution is focused, with 1 pending office action currently on record. This reflects a specific point of contact with the patent office regarding their current research and development outputs and suggests a targeted approach to securing their innovations.
The portfolio's prosecution is concentrated under a distinct examiner and within a distinct art unit. This suggests that the technical merits of the company's current applications are being evaluated by a specialized group. WEN, SHARON X is the busiest examiner for the organization, currently managing 1 pending office action. Because this examiner is the only individual currently reviewing the company's work, the success of their immediate patenting goals depends on the specific requirements and examination style of this individual within the pharmaceutical sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEN, SHARON X | 1 | 56.9% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18459879 | CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1 | WEN, SHARON X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18459879 | CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1 | WEN, SHARON X | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18459879 | CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1 | WEN, SHARON X | 1641 | §102§103 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial